Dáil Éireann Debate, Thursday - 1 July 2021
372. Deputy Marian Harkin asked the Minister for Health the timeline for the inquiry into the historical licensing and prescribing of sodium valproate which he announced in November 2020; the timeline to establish a stakeholder group to review safety and risk measures in relation to the prescribing and distribution of sodium valproate; and if he will make a statement on the matter. [28505/21]
View answer385. Deputy Neale Richmond asked the Minister for Health when the inquiry into the historical licensing and prescribing of sodium valproate will be established after it was announced in November 2020; and if he will make a statement on the matter. [28536/21]
View answer400. Deputy Catherine Connolly asked the Minister for Health the status update on the inquiry into the historical licensing and use of sodium valporate in Ireland; when the terms of reference will be published; the status of the establishment of a stakeholder group to address ongoing concerns relating to the use of sodium valporate; the membership of the stakeholder group; and if he will make a statement on the matter. [28673/21]
View answer432. Deputy Paul Murphy asked the Minister for Health if he will promptly establish an inquiry into the historical licensing and prescribing of sodium valproate as announced in November 2020. [29014/21]
View answer470. Deputy John Paul Phelan asked the Minister for Health when the inquiry into the historical licensing and prescribing of sodium valproate to epilepsy patients will be established; and if he will make a statement on the matter. [29177/21]
View answerI propose to take Questions Nos. 372, 385, 400, 432 and 470 together.
Details of the proposed inquiry into the historical licensing and use of sodium valproate in Ireland and the establishment of a stakeholder group to address ongoing concerns relating to the use of this drug are currently being considered by officials within the Department of Health.
